Navigation Links
The Binding Site Announces Trading Update for Year Ended September 30th 2008
Date:11/11/2008

BIRMINGHAM, England, November 11 /PRNewswire/ --

- Revenues Expected to be up 26%, Freelite(TM) Sales up More Than 50%

The Binding Site Limited ("The Binding Site" or the "Company"), a privately-owned specialist UK diagnostics company, today announces a trading update for the year ended 30th September 2008. The full audited results will be announced in early December 2008.

Revenues are expected to be GBP38.9 million, representing sales growth of approximately 26% in comparison to the previous financial year. The Company has seen strong growth across all its major markets, with approximately 25% growth in revenues in the U.S. and similar growth rates seen in Europe and emerging markets.

The progress has been driven by continued strong demand for Freelite(TM), which is used for the diagnosis and monitoring of multiple myeloma, a cancer of cells in the bone marrow. Sales of Freelite are expected to be up by around 52% at GBP12.6 million in the year to the end of September, underlining the increasing acceptance of the product.

Autoimmune product sales increased approximately 22% to GBP13.6 million year on year, strongly outperforming their market as The Binding Site gained market share and increased its level of new business. The performance was buoyed by the solid growth of newly introduced products and a rise in the base of installed instruments. Sales from the Company's core products business have increased by around 10% to GBP12.7 million in the period, supported by continuing technical improvements and promotional activities.

Commenting on today's announcement, Paul Duncan, Chief Executive Officer of The Binding Site, said:

"This has been an excellent year for The Binding Site and we expect the considerable growth in revenues to be reflected in a strong increase in EBITDA figures. Freelite continues to gain market recognition, with more than 100 scientific publications appearing during the last 12 months. With
'/>"/>

SOURCE The Binding Site Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ProImmune Launches New MHC-Peptide Binding Assay for Class II HLA Alleles
2. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
3. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
4. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
5. Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Prairie Heart Institute of Illino...ly awarded two statuettes at the first-ever CLIO H.... The CLIO Healthcare Awards recognizes creative e...sing industry and is an extension of the CLIO Awar...etitions for advertising, design and interactive. ...
(Date:12/1/2009)...wswire-FirstCall/ -- Palatin Technologies, Inc. (N...ent and Trademark Office has issued U.S. Patent No...nstructs." The claims in the issued patent cover ...tic peptide receptor A (NPRA), including PL-3994, ... "Our natriuretic compounds, including PL-3994, ad...
(Date:12/1/2009)...wswire-FirstCall/ -- Medizone International, Inc. ... tests involving its proprietary AsepticSure(TM) t...nation barriers, this time with two very different...d Bacillis subtilis. These results clearly establi...al technology. "The implications of a 6.7 log redu...
(Date:12/1/2009)...tarian organizations will collaborate in comprehen...r technologies. Their shared efforts will begin in... , Dallas, TX (PRWEB) Dec...randum of Understanding, Mercy Ships and MediSend ...p develop sustainable infrastructure in hospitals ...
Breaking Biology Technology:Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 2Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate 3Medizone International Takes Aim at the Bioterrorism Countermeasures Arena 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 3
...by Investigators from Tumor Institute in ...ell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC...ology has published the results of an innovative s... dose Zevalin(R) ([90Y]-ibritumomab tiuxetan),foll...tients (median age 62,years) with relapsed/refract...
...today announced the launch of the Mattel UCLA Nano...of personalized medicine for children, including t...s one of the world,s first dedicated solely to nan...op a nanopediatrics program? Because children are ...an-in-chief of Mattel Children,s Hospital and foun...
...ms Inc.,(AMEX: PLC ) today announced that it has ...e that would demonstrate its ability to regain,com...ordingly, the company,anticipates that its common ...hange in the next several weeks, and begin to trad...viously announced, PLC received a notice of failur...
Other Biology Technology:High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma 2High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma 3High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma 4High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma 5Mattel Children's Hospital UCLA launches program in nanopediatrics 2PLC Systems Expects Common Stock To Be Delisted From American Stock Exchange 2PLC Systems Expects Common Stock To Be Delisted From American Stock Exchange 3
(Date:11/30/2009)...CLEMSON Clemson University researchers Ron Falta ...nmental Protection Agency grant to study the safe ... located deep below the earth,s surface. , With ... believed to be the leading cause of global warmin...promising alternatives for reducing emissions usin...
(Date:11/30/2009)...his release is available in German . , The ...borative Research Centres as of 1 January 2010. Th...ts Committee in Bonn. The new centres will initial...llion. In addition, 20 percent overhead funding fo...oject. The centres, research topics range from mod...
(Date:11/30/2009)...e Editors of The Journal of Experimental Biology ...m Centre National de la Recherche Scientifique (CN...he winner of this year,s JEB Outstanding Paper P...utstanding achievement and is intended to encourag... Editor-in-Chief, and adds that ,we truly appreci...
Breaking Biology News(10 mins):DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4Mothers immune system may block fetal treatments for blood diseases 9590 1Mothers immune system may block fetal treatments for blood diseases 9590 2Mothers immune system may block fetal treatments for blood diseases 9590 3New nanolaser key to future optical computers and technologies 13581 1New nanolaser key to future optical computers and technologies 13581 2New nanolaser key to future optical computers and technologies 13581 3CAS REGISTRY 28SM 29 the Global Standard for Chemical Research Approaches 50 Millionth Registration Milestone 54595 1CAS REGISTRY 28SM 29 the Global Standard for Chemical Research Approaches 50 Millionth Registration Milestone 54595 2
...ernational, Inc. (OTC Bulletin Board: BKYI), a lea...ireless public safety solutions, announced today t...land Security Investor Conference to be held durin...g BIO-key,s participation at the conference are pr...s Homeland Security Investor Conference: To be he...
...se Biometrics came in,first place in the global SI...d Mobile Congress - the world,s largest event for ...solution is based on Precise Match-on-SIM(TM) and,...ition and mobile phones. , SIMagine is a globa... for,mobile communication and Java cards. The comp...
...stranded seabirds washed up on the shores of Monte...oated with an unknown substance. After an intensiv...ive "red tide" bloom of marine algae had produced ...ral waterproofing from the birds, feathers. , Th...imilar events may have gone undetected in the past...
Other Biology News:BIO-key(R) Announces Conference Schedule 2Mobile Communication Market Opens up for Biometrics - Precise Biometrics Awarded 1st Prize at GSMA World Mobile Congress 2Study links seabird deaths to soap-like foam produced by red-tide algae 2
... is critical to the maintenance of appropriate lev...rtant and diverse as those involved in cellular me...presentation, modulation of cell surface receptors...ption, and signalling factors. The ubiquitin-prote...
... is critical to the maintenance of appropriate lev...rtant and diverse as those involved in cellular me...presentation, modulation of cell surface receptors...ption, and signalling factors. The ubiquitin-prot...
...A modified digital scanner serves as the spot-pick...ive standard rack positions on the tray, leaving s...g two racks.,The software allows for manual select...gel image. The individual x,y-coordinates, togethe...
Telomerase ELISA Assay Kit, TRAPEZE from CHEMICON
Biology Products: